Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models

Front Immunol. 2024 Jan 23:15:1331003. doi: 10.3389/fimmu.2024.1331003. eCollection 2024.

Authors

Roberta Lotti^{1

2}, Jennifer E Hundt³, Ralf J Ludwig³, Christoph M Hammers³, Brydon Bennett², Antonino Amato², Alessandra Marconi^{1

2}, Carlo Pincelli^{1

2}

Affiliations

¹ DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
² PinCell s.r.l., Milan, Italy.
³ Lübeck Institute of Experimental Dermatology, University of Lübeck, Lubeck, Germany.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1193032.].

Keywords: FasL; acantholysis; drug development; ex-vivo model; pemphigus.

Copyright © 2024 Lotti, Hundt, Ludwig, Hammers, Bennett, Amato, Marconi and Pincelli.

Publication types

Published Erratum